Human BCMA Targeted T Cells not checked

Hrain Biotechnology Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“A single dose of predetermined level CAR-positive T cells will be infused.”In the company’s words, NCT05594797 on ClinicalTrials.gov
Tested for
Multiple Myeloma
Main trialPhase 2
“A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection(BCMA CAR-T) Therapy for R/R MM. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of BCMA CAR+ T cells.”In the company’s words, NCT05594797 on ClinicalTrials.gov
Other names
BCMA CAR-T

Other drugs for Multiple Myeloma

All 133 drugs for Multiple Myeloma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Jul 2025 Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
Phase 1Unknown Jul 2022 Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Human BCMA Targeted T Cells

Following is part of Solo: you see every change to Human BCMA Targeted T Cells the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in